Newly developed drugs for osteoporosis in overseas and their future roles for the therapy

Bisphosphonates are widely used, though gastrointestinal tolerance is a problem on daily administration. Intermittent regimen, from once weekly to once yearly, is now available in overseas and can overcome GI adverse events. New generation of anti-resorptive agents (anti-RANKL antibody and a new SER...

Full description

Saved in:

Bibliographic Details
Published in:	Clinical calcium Vol. 18; no. 10; p. 1483
Main Authors:	Wada, Seiki, Fukawa, Takeshi, Kamiya, Sadahiro
Format:	Journal Article
Language:	Japanese
Published:	Japan 01-10-2008
Subjects:	Anabolic Agents Antibodies, Monoclonal Antibodies, Monoclonal, Humanized Bone Density Conservation Agents - therapeutic use Bone Resorption - drug therapy Denosumab Diphosphonates Drug Design Evidence-Based Medicine Fractures, Bone - etiology Fractures, Bone - prevention & control Humans Imidazoles Indoles Organometallic Compounds Osteoporosis - drug therapy RANK Ligand - immunology Selective Estrogen Receptor Modulators Teriparatide Thiophenes
Online Access:	Get more information
Tags:	Add Tag No Tags, Be the first to tag this record!

Description
Summary:	Bisphosphonates are widely used, though gastrointestinal tolerance is a problem on daily administration. Intermittent regimen, from once weekly to once yearly, is now available in overseas and can overcome GI adverse events. New generation of anti-resorptive agents (anti-RANKL antibody and a new SERM, bazedoxifene) are promising and will be soon available for the treatment of osteoporosis. Anabolic agents such as teriparatide and strontium ranelate have marked effects on BMD and reduction on fracture risk. While none of these options is suitable for everyone, the range of future available therapies does mean that most patients can find an intervention that is effective and acceptable.
ISSN:	0917-5857